Rajesh Kumar
Stock Analyst at HSBC
(2.64)
# 2,125
Out of 5,182 analysts
33
Total ratings
50%
Success rate
4.6%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Downgrades: Reduce | $1,070 → $850 | $953.30 | -10.84% | 4 | Mar 17, 2026 | |
| PFE Pfizer | Maintains: Buy | $29 → $32 | $27.47 | +16.49% | 2 | Mar 17, 2026 | |
| BIIB Biogen | Maintains: Reduce | $143 → $150 | $179.90 | -16.62% | 2 | Mar 17, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $60 | $59.20 | +1.35% | 3 | Mar 17, 2026 | |
| ABBV AbbVie | Upgrades: Buy | $225 → $265 | $211.59 | +25.24% | 5 | Dec 10, 2025 | |
| NVO Novo Nordisk | Downgrades: Hold | n/a | $37.61 | - | 3 | Nov 24, 2025 | |
| IQV IQVIA Holdings | Upgrades: Buy | $195 → $235 | $172.54 | +36.20% | 2 | Oct 9, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $25.84 | +62.54% | 1 | Apr 25, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $503.46 | +33.08% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $196.19 | +42.72% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $460 | $305.98 | +50.34% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $30.52 | -57.40% | 1 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $52.10 | +86.18% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $92.08 | +34.67% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $123.18 | -0.15% | 1 | Jul 14, 2023 |
Eli Lilly and Company
Mar 17, 2026
Downgrades: Reduce
Price Target: $1,070 → $850
Current: $953.30
Upside: -10.84%
Pfizer
Mar 17, 2026
Maintains: Buy
Price Target: $29 → $32
Current: $27.47
Upside: +16.49%
Biogen
Mar 17, 2026
Maintains: Reduce
Price Target: $143 → $150
Current: $179.90
Upside: -16.62%
Bristol-Myers Squibb Company
Mar 17, 2026
Maintains: Hold
Price Target: $53 → $60
Current: $59.20
Upside: +1.35%
AbbVie
Dec 10, 2025
Upgrades: Buy
Price Target: $225 → $265
Current: $211.59
Upside: +25.24%
Novo Nordisk
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $37.61
Upside: -
IQVIA Holdings
Oct 9, 2025
Upgrades: Buy
Price Target: $195 → $235
Current: $172.54
Upside: +36.20%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $25.84
Upside: +62.54%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $503.46
Upside: +33.08%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $196.19
Upside: +42.72%
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $305.98
Upside: +50.34%
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $30.52
Upside: -57.40%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $52.10
Upside: +86.18%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $92.08
Upside: +34.67%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $123.18
Upside: -0.15%